Freeline’s retrenchment adds to the growing list of reorganizations, job cuts and other strategic maneuvers young drugmakers have pursued amid a sharp downturn in the public markets.
Already this year, at least 56 biotech companies have announced layoffs, according to a BioPharma Dive tally. More than ten of those companies are gene and cell therapy developers, which were hit particularly hard early on in the sector’s pullback.